VENKATESH K. NADAR, M.D., F.A.C.C.

 

 

PERSONAL INFORMATION:

 

DATE OF BIRTH:                                              May 29, 1961

 

PLACE OF BIRTH:                                            India

 

CITIZENSHIP:                                                   USA

 

HOME ADDRESS:                                            10 Maybelle Court

Mechanicsburg, PA 17050

 

HOME TELEPHONE:                                        717-728-3999

____________________________________________________________________________________

 

PROFESSIONAL INFORMATION:

 

PROFESSIONAL ADDRESS:

2014 to present                                                Holy Spirit Cardiology – A Geisinger Affiliate

875 Poplar Church Road, Suite 400

Camp Hill, PA 17011

 

2012 to 2014                                                     Lewin & Nadar Cardiology Associates

Holy Spirit Cardiovascular Institute

425 North 21st Street, Suite 102

Camp Hill, PA 17011

 

1993 to 2012                                                     Heritage Cardiology Associates

425 North 21st Street, Suite 102

Camp Hill, PA  17011

 

2014 to present                                               Capital Area Research, LLC

875 Poplar Church Road, Suite 330

Camp Hill, PA  17011

 

2012 to 2014                                                    Capital Area Research, LLC

425 North 21st Street, Suite 102

Camp Hill, PA  17011

 

2012 to 2014                                                     Capital Area Research, LLC

46 Red Hill Court

Newport PA, 17074

 

2014 to present                                                Capital Area Research, LLC

52 Red Hill Court

Newport PA, 17074

 

WORK TELEPHONE:                                        717-441-1725

 

 

 

 

PRESENT POSITION:                                       Practicing Interventional Cardiologist at Lewin & Nadar Cardiology Associates, Cardiology,

Director of Clinical Research,

Proficient in Echocardiography, TEE,

Holter, Stress Test, Nuclear Cardiology,

Clinical Research Trials

____________________________________________________________________________________

 

EDUCATION:

 

HIGH SCHOOL:                                                Infant Jesus Anglo Indian High School

Quilon, India

 

COLLEGE:                                                       Sourashtra College

Madurai, India

August 1977 to April 1985

Degree earned: MD

 

MEDICAL SCHOOL:                                         Madras Medical College

Madras, India 1978-1985

Degree earned: MBBS

 

 

RESIDENCY:                                                    Marshall University Affiliated Hospitals

Huntington, WV 1987-1990

 

 

FELLOWSHIP:                                                  Cardiovascular Medicine

Marshall University Affiliated Hospitals

Huntington, WV 25701    1990-1993

__________________________________________________________________________________________

 

 

HOSPITAL AFFILIATIONS:                               Holy Spirit Hospital – 1993 to Present

503 North 21st Street

Camp Hill, PA 17011

 

Pinnacle Health System – 1993 to Present

111 South Front Street

Box 8700

Harrisburg, PA 17101

 

Health South Rehab

LifeCare Hospitals of Mechanicsburg – Director of Cardiology

 

 

BOARD CERTIFICATIONS:                               American Board of Internal Medicine – 1990

American Board of Cardiovascular Diseases – 1995

Certification Board of Nuclear Cardiology – 2001

 

LICENSURE:                                                    Pennsylvania

 

 

 

 

MEMBERSHIPS:                                               American Medical Association

American College of Physicians

American College of Cardiology

Dauphin County Medical Society

Pennsylvania Medical Society

 

COMMITTEES:                                                 Holy Spirit Hospital Institutional Review Board – Chairman

Pharmacy and Therapeutics committee of Holy Spirit Hospital

Pharmacy and Therapeutics committee of Blue Cross

P&T committee

 

REFERENCES:                                                 Available upon request

 

HONORS:                                                         Awarded a Gold Medal for the highest score

in Pre-Med

 

INTERESTS:                                                     Travel, Tennis, Reading

 

RESEARCH & PUBLICATIONS:

 

  • Drug Trial On Milrinone, Carvedilol & Nitrates

 

  • “Blockade of the GPIIB/IIIA Receptor to Avoid Vascular Occlusion (BRAVO)”

Sponsor:   SmithKline Beecham

June 1999 to December 2000

 

  • “Efficacy and Safety of the Oral Direct Thrombin Inhibitor H376/95 Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke & Systemic Embolic Events in Patients with Atrial Fibrillation

(SPORTIF V)”

Sponsor: AstraZeneca

August 2001 to 2003

 

  • “A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the

Efficacy and Safety of Ad5FGF-4 in Patients with Stable Angina (AGENT 3)”

Sponsor:  Berlex, Schering

November 2001 to January 2004

 

  • “A Double-Blind, Placebo-Controlled, Parallel, Multicenter Study on Extended VTE Prophylaxis in Acutely Ill Medical Patients With Prolonged Immobilization (EXCLAIM).”

Sponsor:  Aventis

October 2002

 

  • “A 28 Day, Double-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Phase II Study to Examine the Safety, Tolerability and Effects of SB-480848 on Lp-PLA2 Activity in Dyslipidemic patients.(LPL)”

Sponsor: GlaxoSmithKline

April 2003 to May 2003

 

  • “A Twelve-Week, Randomized, Open-Label, Three-Arm, ParallelGroup, Multicenter, Phase IIIb Study Comparing the Efficacy and Safety of Rosuvastatin 20mg and 40mg with That of Atorvastatin 80mg in Subjects with Acute Coronary Syndromes (LUNAR).”

Sponsor: AstraZeneca

 

  • “A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifibatide in the Treatment of Patients with Non-ST-Segment Evaluation Acute Coronary Syndrome (EARLY ACS).”

Sponsor: Duke Clinical Research Institute

July 2004

 

 

 

  • “A Double-Blind, Double Dummy, Parallel Group, Randomized Dose Confirmation and Feasibility Study of AZD6140 plus ASA Compared with Clopidogrel plus ASA in Patients with Non-ST Elevation Acute Coronary Syndromes (DISPERSE 2).”

Sponsor: AstraZeneca

September 2004

 

  • “A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Dose-Response Study to Evaluate the Efficacy and Safety of Fasudil in Patients with Stable Angina (FASUDIL).”

Sponsor:  Berlex, Schering,

October 2004

 

  • “An Open, Nonrandomized Comparison of Pharmacokinetic Profiles of Carvedilol MR and IR on repeat Dosing in Chronic CHF Patients and Survivors of an Acute MI and LVD (Coreg369)”

Sponsor: GlaxoSmithKline

October 2004

 

  • “A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Rosuvastatin (Crestor) 20mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated C-Reactive Protein (JUPITER).”

Sponsor: AstraZeneca

December 2004

 

  • “A Randomized, Double Blind, Multicenter Study Comparing the Effects of Carvedilol MR and Atenolol in Combination with and Compared to an ACE Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (CLEVER).”

July 2005 to March 2009

 

  • “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Thrombin Receptor Antagonist in PCI [TRA-PCI])”

Sponsor:  Schering-Plough

November 2005

 

  • “A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (exetimibe/Simvastatin tablet) vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (ACS) (IMPROVE-IT)”

Sponsor:  Duke Clinical Research Institute

December 2005 to 2014

 

  • “A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel-group, dose-ranging study of SB-480848, an Oral Lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, in Subjects With Stable Coronary Heart Disease (CHD) or CHD-risk Equivalent to Examine Chronic Inhibition of Lp-LPA2, Effects on Circulating Biomarkers Associated with Cardiovascular Risk, Safety and Tolerability over 12 Weeks (LPL)”

Sponsor: GlaxoSmithKline

January 2006

 

  • “A Randomized, Double-Blind, Double Dummy, Parallel Group, Placebo Controlled Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response and Safety and Tolerability of SB424323 (250mg, 375mg, and 500 mg) Administered Twice Daily for 16 Weeks, on top of Aspirin (325mg qd) in Men and Women with Non Valvular Atrial Fibrillation at a low or Intermediate Risk for Stoke (ITI101724)”

Sponsor:  GlaxoSmithKline

March 2006

 

  • “Randomized Evaluation of Long term anticoagulation therapy comparing the efficacy and safety of two blinded doses of dabigitran etexilate with open label warfarin for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: prospective, multi-centre, parallel-group, non-inferiority trial (RE-LY)”

Sponsor:  Boehringer Ingelheim.

May 2006 to September 2009

 

  • “A Placebo-Controlled, Double-Blind, Parallel Arm Trial to assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization of Death From any Cause in Patients with Atrial Fibrillation/Atrial Flutter (ATHENA)”

Sponsor: Sanofi-Aventis

June 2006

 

  • “A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed Doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four or More Antihypertensive Drugs, Including a Diuretic (DAR-311)”

Sponsor:  Myogen

July 2006 to 2011

 

  • “International, Multicenter, Randomized, Parallel Group, Double-Blind study, in Patients with Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs, Demonstrating the Bioequipotency at Steady State of Equimolar Doses of SSR126517E (3.0 mg) Once a Week and SR34006 (2.5 mg) Once a Week, Documenting the Safety and Efficacy of Both Compounds during a 6-Month Treatment, and Demonstrating the Neutralizing Effect of SSR29261 on the SSR126517E-induced Anti-Xa Activity (EQUINOX)”

Sponsor: Sanofi-Aventis

October 2006

 

  • “An International, Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group Study of 3-Month or 6-Month Treatment with SSR126517E (3.0 mg s.c Once Weekly) Versus Oral INR-Adjusted Warfarin in the Treatment of Patients with Symptomatic Pulmonary Embolism, with or without Symptomatic Deep Vein Thrombosis (CASSIOPEA)”

Sponsor: Sanofi-Aventis

October 2006 to 2010

 

  • “A Randomized, Double-Blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (PLATO)”

Sponsor: AstraZeneca

February 2007

 

  • “A phase 3 active (warfarin) controlled, randomized, double-blind, Parallel arm study to evaluate efficacy and safety of apixaban in preventing stroke and systemic embolism in subjects with non-valvular atrial fibrillation (ARISTOTLE)

Sponsor: Bristol Myers Squibb

May 2007 to 2011

 

  • “Double-Blind, Placebo-Controlled, Multicenter, acute study of clinical effectiveness of Nesiritide in subjects with decompensated heart Failure (ASCEND)

Sponsor: Scios

September 2007 to 2010

 

  • “A randomized, multicenter, study to evaluate the pharmacokinetics, Pharmacodynamics, and safety of Rivaroxaban in subjects with acute (Open-Label, Active-Controlled) or chronic (Double-Blind, Placebo Controlled) congestive heart failure (IMPACT)

Sponsor: Johnson & Johnson

February 2008 to March 2009

 

  • “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA)

Sponsor: Schering Plough Research Institute

February 2008 to 2012

 

 

 

 

  • “A randomized double-blind, placebo-controlled, study of the safety and Tolerability of E5555, and its effects on markers of intravascular Inflammation in subjects with coronary artery disease (LANCELOT)

Sponsor: Esai

May 2008 to 2010

 

  • “A phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS) (DAL OUTCOMES)

Sponsor: Roche

June 2008 to 2012

 

  • “A Multinational, multicenter, randomized, double-blind study comparing the efficacy and safety of AVE5026 with enoxaparin for the primary prevention of venous thromboembolism in acutely ill medical patients with restricted mobility (SAVE)

Sponsor: sanofi-aventis, US

October 2008

 

  • “RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomized Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes (RELY-ABLE)

Sponsor: Boehringer Ingelheim Pharmaceuticals

December 2008 to 2012

 

  • “Randomized, double-blind, placebo-controlled, parallel-group study to Assess the effects of intravenous BG9928 on body weight in subjects with Acute decompensated heart failure and renal insufficiency (TRIDENT)

Sponsor: Biogen Idec

February 2009 to September 2009

 

  • “A Randomized Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy (TECOS)

Sponsor: Merck

March 2009 to Present

 

  • “SMARTDELAY Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy (SMART-AV)

Sponsor: Boston Scientific

April 2009 to 2010

 

  • “Multicenter, randomized, parallel group efficacy and safety study for Prevention of venous thromboembolism in hospitalized medically ill patients Comparing Rivaroxaban with Enoxaparin (MAGELLAN)

Sponsor: Bayer Healthcare Pharmaceuticals

May 2009 to 2011

 

  • “A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multi-Center, Multi-National Study for Evaluation of Efficacy and Safety of DU-176b versus Warfarin in Subjects with Atrial Fibrillation – Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE)

Sponsor: Daiichi Sankyo Inc.

September 2009 to 2013

 

  • “PROspective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE)”

Sponsor: NIH

December 2010 to 2014

 

  • “TRANSLATE-ACS – TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (Translate-ACS) Registry”

Sponsor: Lilly

Jun 2011 to 2014

 

  • “Treatment Of Preserved Cardiac function heart failure with an Aldosterone anTagonist (TOPCAT)

Sponsor: NHLBI

Jun 2011 to 2013

 

  • “TIMI 57 – A Double-Blind, Randomized, Placebo-controlled, Multicenter, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL group -C in Combination with HMG-CoA Reductase Inhibitors in Hypercholesterolemic Subjects (Amgen)”
    Sponsor: Amgen, Inc.

August 2011 to present

 

  • “A Phase 3, randomized, double-blind, double-dummy parallel-, multi-center, multi-national study for the evaluation of efficacy and safety of (LMW) heparin/edoxaban versus (LMW) heparin/warfarin in subjects with symptomatic deep-vein thrombosis and/or pulmonary embolism (HOKUSAI)

Sponsor:  Daiichi Sankyo Pharma Development

August 2009 to 2013

 

  • “A prospective, open label study evaluating the efficacy of two management strategies (pantoprzole 40mg q.a.m. and taking Pradaxa with food (within 30 minutes after a meal)) on gastrointestinal symptoms (GIS) in patients newly on treatment with Pradaxa 150mg b.i.d. or 75mg b.i.d. for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) PRADAXA

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.

February 2012 to 2014

 

  • “Coreg Heart Failure Registry (COHERE)”

Sponsor:   SmithKline Beecham

May 1999

 

  • “Hypertension Ambulatory Research Trial (HART)”

Sponsor:  Novartis Pharmaceuticals Corp.

June 1999

 

  • “This is a multicenter, randomized, open-label, assessor-blind, event-driven, non-inferiority program for the efficacy with study treatment duration of 3, 6, or 12 months. The program consists of two independent evaluations: 1) one in patients with confirmed acute symptomatic DVT without symptomatic PE (Einstein-DVT), and 2) one in patients with confirmed acute symptomatic PE with or without symptomatic DVT (Einstein-PE).  (EINSTEIN)”

Sponsor:  Bayer Healthcare Pharmaceuticals

November 2007 to 2011

 

  • “Double blind placebo controlled dose ranging study of the efficacy and safety of celivarone at 50,100 300 mg OD with amiodarone as calibrator for the prevention of ICD interventions of death (ALPHEE)

Sponsor: Sanofi-Aventis

September 2009 to 2010

 

  • “A Clinical Outcomes study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) (Short title:  The Stabilization of plaques using Darapladib Thrombolysis in Myocardial Infarction 52

(SOLID-TIMI 52)”

Sponsor:  GlaxoSmithKline

October 2009 to 2014

 

  • “A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrillation and additional risk factors (PALLAS)”

Sponsor: Sanofi-aventis U.S. INC

May 2010 to 2011

 

 

 

  • “A Placebo-Controlled, Double-Blind, Randomized, Multi-Center Study to Assess the Effects of Dronedarone 400mg BID for 12 weeks on Atrial Fibrillation Burden in Subjects with Permanent Pacemakers (HESTIA)

Sponsor:  Sanofi-Aventis U.S. INC.

June 2010 to 2011

 

  • “A Placebo-Controlled, Double-Blinded, Randomized, Multi-center Study to Assess the Effects of Dronedarone 400 mg BID on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement (DRONE 315)”

Sponsor:  Sanofi –Aventis

September 2010 to 2011

 

  • “The ASPECT Trial: A Phase III, Randomized, Double-Blind Crossover Trial of Apadenoson for the detection of Myocardial Perfusion Defects Using Single-Photon Emission” Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)”

Sponsor: Forest

Jan 2011 to Nov 2011

 

  • “The ASPECT2 Trial: A Phase 3, Randomized, Double-Blind Trial of Apadenoson For the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)

Sponsor: Forest

Nov 2011 to 2012

 

  • “A Multi-Center, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Death in Patients with an Implantable Cardioverter Defibrillator (SHIELD-2).”

Sponsor: Forest

2011 to 2013

 

  • “A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of AMR101 on Cardiovascular Health and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardiovascular Disease: REDUCE-IT (Reduction of Cardiovascular Events with EPA-Intervention Trial)”

Sponsor: Amarin

2012 to present

 

  • “Long-term safety and tolerability of REGN727/SAR236553 in high cardiovascular risk

patients with hypercholesterolemia not adequately controlled with their lipid modifying therapy: a

randomized, double-blind, placebo-controlled study (Odyssey)”

Sponsor: Sanofi Aventis

2012 to present

 

  • “A randomized placebo controlled clinical trial to evaluate cardiovascular outcomes after treatment with Exanatide once weekly in patient with Type 2 Diabetes Mellitus (Excel)”

Sponsor: Amilyn

2009 to present

 

  • “D5135C00001: A randomized, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischemic stroke in patients with established Peripheral Artery Disease. EUCLID (Examining Use of tiCagreLor In paD).”

Sponsor: AstraZeneca

Protocol #: D5135C00001

2012 to present

 

  • GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT)”

Sponsor: National Heart Lung and Blood Institute

2012 to 2014

 

 

  • GLORIAAF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients with Atrial Fibrillation (phase II/III)”

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.

2012 to present

 

  • “Multicenter, Randomized, Active-Controlled Efficacy and Safety Study Comparing Extended Duration Betrixaban with Standard of Care Enoxaparin for the Prevention of Venous Thromboembolism in Acute Medically Ill Patients (APEX) (11-019)”

Sponsor: Portola Pharmaceuticals

2012 to present

 

  • “A Randomized, Open-Label, Parallel-Group, Multi-Center Study For The Evaluation Of Efficacy And Safety Of Edoxaban Monotherapy Versus (LMW) Heparin/ Warfarin In Subjects With Symptomatic Deep-Vein Thrombosis – Edoxaban Thrombus Reduction Imaging Study (eTRIS) (DU176b-D-U211)”

Sponsor: Daiichi Sankyo

2012 to 2014

 

  • “Amgen Protocol Number: 20110110: A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145”

Sponsor: Amgen, Inc

2011 to present

 

  • “A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When AMG 145 is Used in Combination With Statin Therapy in Patients with Clinically Evident Cardiovascular Disease (FOURIER) Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk (20110118)”

Sponsor: Amgen, Inc.

2012 to present

 

  • “A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP (Cantos)”

Sponsor: Novartis

2012 to present

 

  • “Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes – the ACCELERATE Study”

Sponsor: Eli Lilly and Company

2012 to present

 

  • “A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging (Ranexa)”

Sponsor: Gilead Sciences, Inc.

2011 to 2012

 

  • “NC25608: A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD) (DAL-OC2)

DAI-OUTCOMES2

Sponsor: Roche

2012

 

  • “A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes (DECLARE-TIMI 58) (D1693C00001)”

Sponsor: AstraZeneca

2013 to present

 

 

  • “Du176b-E-U210: A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention – Edoxaban In Peripheral Arterial Disease (ePAD)”

Sponsor: Daiichi Sankyo

2013 to 2015

 

  • “A Prospective, Randomized, Open-label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) with Enoxaparin/Warfarin followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial Fibrillation (ENSURE-AF) (DU176b-F-E308)”

Sponsor: Daiichi Sankyo

2014 to present

 

  • “A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA) (APD356-G000-401)”

Sponsor: Eisai

2014 to present

 

  • “A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects with Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D) (Protocol GS-US-356-0101) (TEMPO)”

Sponsor: Gilead Science, Inc.

2014 to present

 

  • “A Long-Term Outcomes Study to Assess Statin Residual Risk Reduction with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia (STRENGTH) (D5881C00004)”

Sponsor: AstraZeneca AB

2014 to present

 

  • “The AdaptResponse study is a prospective, randomized, controlled, interventional,

single-blinded, multi-center, post-market, global Cardiac Resynchronization Therapy

(CRT) in heart failure (HF) clinical study. The purpose of this clinical study is to test the

hypothesis that market released CRT devices which contain the AdaptivCRT® (aCRT)

algorithm have a superior outcome compared to standard CRT devices in CRT indicated

patients with normal AV conduction and left bundle branch block (LBBB)”

Sponsor: Metronic, Inc.

2015 to present

 

  • “A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients with Paroxysmal Atrial Fibrillation (AFIB BURDEN) (CV205-005)”

Sponsor: Bristol-Myers Squibb

2014 to present

 

  • “A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients with Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial.

EBBINGHAUS Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects. Amgen Protocol Number: 20130385”

Sponsor: Amgen, Inc.

2015 to present

 

  • “A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus. HARMONY Outcomes Trial GLP116174 (Phase IV)”

Sponsor: GlaxoSmithKline

2015 to present

 

  • “Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) (RIVAROXDVT3002)”

Sponsor: Janssen Research & Development

2014 to present

 

  • “Alirocumab Expanded Access Program for the Treatment of Patients with Severe

Hypercholesterolemia not Controlled with Maximal Tolerated Dose of Lipid-

Lowering Therapy Administered According to Standard of Care (SAR236553/REGN727) – CUP14366”

Sponsor: Sanofi

2015 to present

 

  • “A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus (D513BC00001)

[THEMIS – effect of Ticagrelor on Health outcomes in diabEtes Mellitus patients Intervention Study]”

Sponsor: AstraZeneca

2015 to present

 

  • “An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures. VOYAGER PAD

Protocol Number: BAY 59-7939/17454”

Sponsor: Bayer

2015 to present

 

 

  • Poster presentation sponsored by Pfizer Inc.

“An Analysis of Cholesterol Goal Attainment for

the Implementation of a Cardiology Lipid Clinic”

Thirty-Fourth Annual ASHP Midyear Clinical

Meeting and Exhibits in Orlando, December 1999

 

  • “Contrast Echoes in Aortic Regurgitation”

Published in Journal of Echocardiography

 

  • “Signed Averaged Electrocardiogram in

Trained Athletes” Published in NASPE

 

 

 

 

 

error: Content is protected !!